Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Debt-to-Equity : 1.47 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Debt-to-Equity?

Maravai LifeSciences Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.9 Mil. Maravai LifeSciences Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $598.1 Mil. Maravai LifeSciences Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $416.8 Mil. Maravai LifeSciences Holdings's debt to equity for the quarter that ended in Dec. 2023 was 1.47.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Maravai LifeSciences Holdings's Debt-to-Equity or its related term are showing as below:

MRVI' s Debt-to-Equity Range Over the Past 10 Years
Min: 1.07 Med: 2.09 Max: 6.68
Current: 1.47

During the past 6 years, the highest Debt-to-Equity Ratio of Maravai LifeSciences Holdings was 6.68. The lowest was 1.07. And the median was 2.09.

MRVI's Debt-to-Equity is ranked worse than
92.16% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs MRVI: 1.47

Maravai LifeSciences Holdings Debt-to-Equity Historical Data

The historical data trend for Maravai LifeSciences Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Debt-to-Equity Chart

Maravai LifeSciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

2.76

6.68

1.82

1.07

1.47

Maravai LifeSciences Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial														1.07	1.16	1.19	1.18	1.47

Competitive Comparison of Maravai LifeSciences Holdings's Debt-to-Equity

For the Biotechnology subindustry, Maravai LifeSciences Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maravai LifeSciences Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's Debt-to-Equity falls into.

Maravai LifeSciences Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Maravai LifeSciences Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.853	+	598.114)	/	416.753
	=	1.47

Maravai LifeSciences Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.853	+	598.114)	/	416.753
	=	1.47

Maravai LifeSciences Holdings (NAS:MRVI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Maravai LifeSciences Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MRVI:Mexico MAR:Germany

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Executives

John A Deford	director	C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Rebecca Buzzeo	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii	officer: See remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy	officer: See Remarks	1620 FARADAY AVE, CARLSBAD CA 92008
Carl Hull	director, officer: Chief Executive Officer	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack	officer: General Counsel	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian Neel	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Christine Dolan	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121